Logo image of SBBP

Strongbridge Bio Ord (SBBP) Stock Fundamental Analysis

NASDAQ:SBBP - Nasdaq -

2  +0.03 (+1.52%)

After market: 2.02 +0.02 (+1%)

Fundamental Rating

3

SBBP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SBBP have multiple concerns. SBBP is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SBBP has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -41.48%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -124.18%
PM (TTM) -115.66%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for SBBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.75, we must say that SBBP is in the distress zone and has some risk of bankruptcy.
SBBP has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z -3.75
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 3.00 indicates that SBBP has no problem at all paying its short term obligations.
A Quick Ratio of 2.95 indicates that SBBP has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 2.95

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.38% over the past year.
SBBP shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.98%.
The Revenue has been growing by 63.38% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)49.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)34.98%
Revenue growth 3Y63.38%
Revenue growth 5YN/A
Sales Q2Q%29.41%

3.2 Future

SBBP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.82% yearly.
Based on estimates for the next years, SBBP will show a very strong growth in Revenue. The Revenue will grow by 45.58% on average per year.
EPS Next Y35.78%
EPS Next 2Y29.57%
EPS Next 3Y42.71%
EPS Next 5Y34.82%
Revenue Next Year25.01%
Revenue Next 2Y38.84%
Revenue Next 3Y42.39%
Revenue Next 5Y45.58%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SBBP Yearly Revenue VS EstimatesSBBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
SBBP Yearly EPS VS EstimatesSBBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SBBP. In the last year negative earnings were reported.
Also next year SBBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SBBP Price Earnings VS Forward Price EarningsSBBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.36
SBBP Per share dataSBBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as SBBP's earnings are expected to grow with 42.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.57%
EPS Next 3Y42.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SBBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Strongbridge Bio Ord

NASDAQ:SBBP (10/5/2021, 8:21:57 PM)

After market: 2.02 +0.02 (+1%)

2

+0.03 (+1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2021-11-04
Earnings (Next)03-02 2022-03-02/bmo
Inst Owners0.02%
Inst Owner Change0%
Ins Owners6.77%
Ins Owner Change0%
Market Cap135.66M
Analysts80
Price Target5.1 (155%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.91
P/FCF N/A
P/OCF N/A
P/B 3.06
P/tB N/A
EV/EBITDA -2.36
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.51
BVpS0.65
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -124.18%
PM (TTM) -115.66%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3
Quick Ratio 2.95
Altman-Z -3.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y35.78%
EPS Next 2Y29.57%
EPS Next 3Y42.71%
EPS Next 5Y34.82%
Revenue 1Y (TTM)34.98%
Revenue growth 3Y63.38%
Revenue growth 5YN/A
Sales Q2Q%29.41%
Revenue Next Year25.01%
Revenue Next 2Y38.84%
Revenue Next 3Y42.39%
Revenue Next 5Y45.58%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A